BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Canada: TSX and TSXV Level 1

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1305.00 only $522.00

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.58
-0.02%
US Tech 100
20,327.60
-0.22%
S&P 500
6,021.63
0.57%
US Dollar vs CAD
1.40546
0.01%
Bitcoin
93,194.97
1.33%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Verve Therapeutics Inc (VERV) Share Price

Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

Verbund Ag
Verbund Ag
Verbund Ag
Verbund Ag
5.31
0.02
(0.38%)
Closed November 26 3:00PM
Delayed by 15 minutes
5.31
0.00
( 0.00% )
Pre Market: 3:00AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
5.31
Bid
4.85
Ask
5.59
Volume
-
0.00 Day's Range 0.00
4.305 52 Week Range 19.34
Market Cap
449.565M
Previous Close
5.31
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,343,200
Shares Outstanding
84,663,840
Dividend Yield
-
PE Ratio
-2.25
Earnings Per Share (EPS)
-2.36
Revenue
11.76M
Net Profit
-200.07M

About Verve Therapeutics Inc

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.vervetx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VERV. The last closing price for Verve Therapeutics was US$5.31. Over the last year, Verve Therapeutics shares have traded in a share price range of US$ 4.305 to US$ 19.34.

Verve Therapeutics currently has 84,663,840 shares outstanding. The market capitalization of Verve Therapeutics is US$449.56 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -2.25.

Ask ADVFN Intelligence (AI)

VERV Latest News

More News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 08 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 05 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 05 2024
Edgar (US Regulatory)

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the...

November 05 2024
GlobeNewswire Inc.

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October...

November 01 2024
GlobeNewswire Inc.

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV PR Newswire LOS ANGELES, Oct. 28, 2024 LOS ANGELES, Oct. 28, 2024 /PRNewswire/...

October 28 2024
PR Newswire (US)

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV PR Newswire NEW YORK, Oct. 28, 2024 NEW YORK, Oct...

October 28 2024
PR Newswire (US)

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV PR Newswire LOS ANGELES, Oct. 23, 2024 LOS ANGELES, Oct. 23, 2024 /PRNewswire/...

October 23 2024
PR Newswire (US)

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV PR...

October 17 2024
PR Newswire (US)

Class Action Filed Against Verve Therapeutics, Inc. (VERV) - October 28, 2024 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Verve Therapeutics, Inc. (VERV) - October 28, 2024 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Oct. 14, 2024 NEW YORK, Oct. 14, 2024...

October 14 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.479.710743801654.845.484.4414326794.93838167CS
4-0.61-10.30405405415.926.774.4416619825.54843745CS
12-0.63-10.60606060615.946.774.3713432005.40845581CS
26-0.06-1.117318435755.377.964.30513828675.5513069CS
52-7.11-57.246376811612.4219.344.30513443808.13956766CS
156-28.62-84.35013262633.93434.305103556315.79763258CS
260-24.69-82.330784.30595456017.8443324CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HWHHWH International Inc
US$ 1.195
(111.50%)
3.04M
IFBDInfobird Company Ltd
US$ 2.93
(60.99%)
692.3k
IDAIT Stamp Inc
US$ 0.5378
(47.34%)
5.48M
CYCNCyclerion Therapeutics Inc
US$ 1.83
(34.56%)
295.31k
QMCOQuantum Corporation
US$ 21.89
(27.05%)
73.55k
PGHLPrimega Group Holdings Ltd
US$ 11.85
(-88.96%)
117.17k
NVXNOVONIX Ltd
US$ 2.00
(-25.65%)
87
IMGCIMG Inc
US$ 1.20
(-25.00%)
105.85k
LEGHLegacy Housing Corporation
US$ 20.00
(-22.78%)
99
ALRSAlerus Financial Corporation
US$ 17.00
(-22.66%)
200
IDAIT Stamp Inc
US$ 0.5373
(47.21%)
5.48M
HWHHWH International Inc
US$ 1.20
(112.39%)
3.04M
RGTIRigetti Computing Inc
US$ 2.47
(12.27%)
2M
IFBDInfobird Company Ltd
US$ 2.93
(60.99%)
692.58k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 20.75
(0.83%)
326.72k

VERV Discussion

View Posts
Monksdream Monksdream 3 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 3 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 4 months ago
VERV 10Q due AUGUST5
👍️0
Monksdream Monksdream 5 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 5 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 6 months ago
VERV more new lows up ahead
👍️0
Monksdream Monksdream 6 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 lo
👍️0
Firestorm22 Firestorm22 8 months ago
uh oh
👍️0
Monksdream Monksdream 8 months ago
VERV over $10
👍️0
fink fink 9 months ago
Looking for an entry now
👍️0
Terpi Terpi 1 year ago
Could see another nice move here is the 50 day holds into close.
👍️0
Monksdream Monksdream 1 year ago
VERV morning rally
👍️0
TheFinalCD TheFinalCD 2 years ago
https://cathiesark.com/
👍️0
crudeoil24 crudeoil24 2 years ago
VERV IS A GREAT $$$$$ OPPORTUNITY.
👍️0
crudeoil24 crudeoil24 2 years ago
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
👍️0
crudeoil24 crudeoil24 2 years ago
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
👍️0

Your Recent History

NASDAQ
VERV
Verve Therapeutics
LSE
0LYB
Zaklady Magnezytowe Ropc...
BIT
SXLU
Spdr S&p U.s. Utilities ...
CSE
PHI
Philippine Metals
BIT
P1HKZ2
BNP Paribas Issuance BV
BIT
P1KOC7
BNP Paribas Issuance
BIT
P14Y59
BNP Paribas Issuance
BIT
ALFO
Alfonsino
BOV
NMRH34
Nomura
NASDAQ
AFRIW
Forafric Global
EU
EXCH
iShares MSCI EM EX China...
BOV
BHYG39M
BlackRock Institutional ...
BOV
SANB11Q
SANTANDER BR
NASDAQ
ACGL
Arch Capital
NYSE
JCI
Johnson Controls
NYSE
TRGP
Targa Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Canada: TSX and TSXV Level 1

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1305.00 only $522.00